Andere talen I-Mab BOERSE MUENCHEN

Aandelen

0VY

US44975P1030

Real Time BOERSE MUENCHEN Andere beurzen 21:44:03 27-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,58 ^EUR	-2,47%		-2,41%	-2,99%

06/06	I-Mab benoemt Phillip Dennis tot Chief Medical Officer	CI
05/06	I-Mab werkt samen met Bristol-Myers om givastomig te evalueren in een combinatiestudie voor maag- en slokdarmkanker	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	07/06
I-Mab Appoints Phillip Dennis as Chief Medical Officer	06/06
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	23/05
I-Mab to Participate at the Jefferies Global Healthcare Conference	22/05
I-MAB Filed 2023 Annual Report on Form 20-F	30/04
Verastem Names John Hayslip as Chief Medical Officer	18/04
I-Mab Announces Chief Medical Officer Changes	15/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	08/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	05/04
I-Mab Completes Business Divestiture in China	02/04
I-Mab Announces Closing of the Divestiture of Business Operations in China	02/04
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04
I Mab : Resignations of Director and Senior Management - Form 6-K	01/04
I-Mab Announces Executive Resignation	01/04
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
I-Mab Divests China Operations, Shifts Focus to US Market	09/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen I-Mab BOERSE MUENCHEN

Aandelen

0VY

US44975P1030

Andere talen

Filters